


Gateway® TurboGFP-N entry clone

The vector sequence has been compiled using the information from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced.



For vector sequence, please visit our Web site at <http://www.evrogen.com/support/vector-info.shtml>

Gateway® TurboGFP-N vector MCS

... attL1 site AGG . CTG . CTA . GCG . CTA . CCG . GAC . TCA . GAT . CTC . GAG . CTC . AAG . CTT . CGA . ATT . CTG . CAG . TCG . ACG . GTA . CCG . CGG . GCC . CGG . GAT . CCA . CCG . GTC . GCC . ACC . ATG . G . . . TurboGFP
Afe I Bgl II Sac I EcoR I Sal I Sac II Sma I/Xma I Age I
Xho I Hind III Pst I* Kpn I Apa I* BamH I Nco I*

* — not unique sites.

Location of features

attL1 site: 14-113
MCS: 117-194
Kozak translation initiation site: 195-205
TurboGFP: 202-900
attL2 site: 919-1018
Kanamycin resistance gene: 2236-3030
pUC origin of replication: 3615-4258

References

Haas et al. (1996) "Codon usage limitation in the expression of HIV-1 envelope glycoprotein." *Curr Biol*, 6 (3): 315-324 / pmid: 8805248
Kozak (1987) "An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs." *Nucleic Acids Res*, 15 (20): 8125-8148 / pmid: 3313277
Gateway® Technology. Ver. E. 22 Sept. 2003, 25-0522. <http://www.invitrogen.com/content/sfs/manuals/gatewayman.pdf> (visited on 18.06.2008)

Product	Cat.#	Size
Gateway® TurboGFP-N entry clone	FP522	20 µg
The price does not include delivery. The price varies in different countries. Please contact your local distributor for exact prices and delivery information.		
Vector type	Gateway® entry clone	
Reporter	TurboGFP	
Reporter codon usage	mammalian	
Promoter for TurboGFP	NO	
Host cells	prokaryotic	
Selection	kanamycin	
Replication	pUC ori	
Use	Generation of fusions to the N-terminus of TurboGFP; transfer of the construct encoding TurboGFP or its fusion into Gateway® destination vectors	

Vector description

Gateway® TurboGFP-N entry clone is a vector containing green fluorescent protein TurboGFP gene variant with codon usage optimized for high expression in mammalian cells (humanized) [Haas et al. 1996]. TurboGFP coding sequence is flanked by attL1 and attL2 sites allowing easy site-specific recombination. The Invitrogen Gateway® Technology provides a rapid and highly efficient way to transfer the TurboGFP gene into a number of Gateway® destination vectors for expression in different experimental systems. Multiple cloning site (MCS) located at the 5'-end of TurboGFP gene allows to generate fusions to the TurboGFP N-terminus for expression, localization and cellular dynamics studies.

To increase mRNA translation efficiency, Kozak consensus translation initiation site is generated upstream of TurboGFP coding sequence [Kozak 1987].

The vector backbone contains pUC origin of replication and kanamycin resistance gene (Kan^r) for propagation and selection in *E. coli*.

Generation of TurboGFP-tagged fusions

A localization signal or a gene of interest can be cloned into MCS of the vector both before and after site-specific recombination with a destination vector. It will be expressed as a fusion to the TurboGFP N-terminus when inserted in the same reading frame as TurboGFP and no in-frame stop codons are present.

Alternatively, TurboGFP gene can be fused to the 3'-end of a gene of interest by LR recombination of the Gateway® TurboGFP-N with a destination vector containing this gene in a correct reading frame.

TurboGFP-tagged fusions retain fluorescent properties of the native protein allowing fusion localization *in vivo*.

Note: The plasmid DNA was isolated from dam⁺-methylated *E. coli*. Therefore some restriction sites are blocked by methylation. If you wish to digest the vector using such sites you will need to transform the vector into a dam⁻ host and make fresh DNA.

LR site-specific recombination

Please refer to Invitrogen Gateway® Technology description for detailed instructions regarding LR site-specific recombination reaction. In general, to transfer TurboGFP gene or TurboGFP-fusion construct into the destination vector you will need:

- Purified plasmid DNA of Gateway® TurboGFP-N
- A destination vector of choice
- Invitrogen LR Clonase™ II enzyme mix (Invitrogen Cat.# 11791-020)
- Proteinase K solution (supplied with the LR Clonase™ II enzyme mix)
- TE-Buffer, pH 8.0 (10 mM Tris-HCl, pH 8.0, 1 mM EDTA)
- Appropriate chemically competent *E. coli* host and growth media for expression
- Appropriate selective plates.

Propagation in *E. coli*

Suitable host strains for propagation in *E. coli* include DH5alpha, HB101, XL1-Blue, and other general purpose strains. Plasmid incompatibility group is pMB1/ColE1. The vector confers resistance to kanamycin (30 µg/ml) to *E. coli* hosts. Copy number in *E. coli* is about 500.

Notice to Purchaser:

Evrogen Fluorescent Protein Products (the Products) are intended for research use only. The Products are covered by U.S. Pat. 7,417,131 and other Evrogen Patents and/or Patent applications pending. By use of these Products, you accept the terms and conditions of the applicable Limited Use Label License.

Invitrogen Gateway® Technology: please see Invitrogen Limited Use Label License N^o. 19: Gateway® Cloning Products.

MATERIAL SAFETY DATA SHEET INFORMATION: To the best of our knowledge, these products do not require a Material Safety Data Sheet. However, all the properties of these products (and, if applicable, each of their components) have not been thoroughly investigated. Therefore, we recommend that you use gloves and eye protection, and wear a laboratory coat when working with these products.